Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 96

Similar articles for PubMed (Select 23656187)

1.

Survival times of women with metastatic breast cancer starting first-line chemotherapy in routine clinical practice versus contemporary randomised trials.

Thientosapol ES, Tran TT, Della-Fiorentina SA, Adams DH, Chantrill L, Stockler MR, Kiely BE.

Intern Med J. 2013 Aug;43(8):883-8. doi: 10.1111/imj.12178. Review.

PMID:
23656187
2.

Estimating scenarios for survival time in men starting systemic therapies for castration-resistant prostate cancer: a systematic review of randomised trials.

West TA, Kiely BE, Stockler MR.

Eur J Cancer. 2014 Jul;50(11):1916-24. doi: 10.1016/j.ejca.2014.04.004. Epub 2014 May 10. Review.

PMID:
24825113
3.

A systematic overview of chemotherapy effects in breast cancer.

Bergh J, J├Ânsson PE, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):253-81. Review.

PMID:
11441936
4.

Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.

Wagner AD, Thomssen C, Haerting J, Unverzagt S.

Cochrane Database Syst Rev. 2012 Jul 11;7:CD008941. doi: 10.1002/14651858.CD008941.pub2. Review.

PMID:
22786517
5.

How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials.

Kiely BE, Soon YY, Tattersall MH, Stockler MR.

J Clin Oncol. 2011 Feb 1;29(4):456-63. doi: 10.1200/JCO.2010.30.2174. Epub 2010 Dec 28. Review.

PMID:
21189397
6.

WITHDRAWN: Multi-agent chemotherapy for early breast cancer.

Clarke MJ.

Cochrane Database Syst Rev. 2008 Oct 8;(4):CD000487. doi: 10.1002/14651858.CD000487.pub2. Review.

PMID:
18843612
7.

Multi-agent chemotherapy for early breast cancer.

Early Breast Cancer Trialists' Collaborative Group.

Cochrane Database Syst Rev. 2002;(1):CD000487. Review. Update in: Cochrane Database Syst Rev. 2008;(4):CD000487.

PMID:
11869577
8.

Estimating typical, best-case and worst-case life expectancy scenarios for patients starting chemotherapy for advanced non-small-cell lung cancer: a systematic review of contemporary randomized trials.

Kiely BE, Alam M, Blinman P, Tattersall MH, Stockler MR.

Lung Cancer. 2012 Sep;77(3):537-44. doi: 10.1016/j.lungcan.2012.04.017. Epub 2012 May 18. Review.

PMID:
22609149
9.

Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design.

Kassam F, Enright K, Dent R, Dranitsaris G, Myers J, Flynn C, Fralick M, Kumar R, Clemons M.

Clin Breast Cancer. 2009 Feb;9(1):29-33. doi: 10.3816/CBC.2009.n.005.

PMID:
19299237
12.

Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis.

Fleeman N, Bagust A, Boland A, Dickson R, Dundar Y, Moonan M, Oyee J, Blundell M, Davis H, Armstrong A, Thorp N.

Health Technol Assess. 2011;15(42):1-93, iii-iv. doi: 10.3310/hta15420. Review.

13.

HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.

Kim JW, Kim JH, Im SA, Kim YJ, Han HS, Kim JS, Lee KH, Kim TY, Han SW, Jeon YK, Oh DY, Kim TY, Park IA.

Cancer Chemother Pharmacol. 2013 Jul;72(1):109-15. doi: 10.1007/s00280-013-2174-1. Epub 2013 May 15.

PMID:
23673443
14.

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M.

J Clin Oncol. 2009 Nov 20;27(33):5538-46. doi: 10.1200/JCO.2009.23.3734. Epub 2009 Sep 28.

15.

Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.

Pentheroudakis G, Fountzilas G, Bafaloukos D, Koutsoukou V, Pectasides D, Skarlos D, Samantas E, Kalofonos HP, Gogas H, Pavlidis N.

Breast Cancer Res Treat. 2006 Jun;97(3):237-44. Epub 2005 Dec 2.

PMID:
16322882
16.

Single agent versus combination chemotherapy for metastatic breast cancer.

Carrick S, Parker S, Thornton CE, Ghersi D, Simes J, Wilcken N.

Cochrane Database Syst Rev. 2009 Apr 15;(2):CD003372. doi: 10.1002/14651858.CD003372.pub3. Review.

PMID:
19370586
17.

Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor.

Linderholm B, Bergqvist J, Hellborg H, Johansson U, Linderholm M, von Schoultz E, Elmberger G, Skoog L, Bergh J.

Med Oncol. 2009 Dec;26(4):480-90. doi: 10.1007/s12032-008-9157-9. Epub 2009 Jan 7.

PMID:
19130322
18.

Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial.

Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE.

J Natl Cancer Inst. 2012 Mar 7;104(5):406-14. doi: 10.1093/jnci/djr543. Epub 2012 Jan 16.

19.
20.

Better estimates of survival for patients considering adjuvant chemotherapy after surgery for early non-small-cell lung cancer.

McCaughan GJ, Blinman PL, Boyer MJ, Stockler MR.

Intern Med J. 2013 Apr;43(4):424-9. doi: 10.1111/j.1445-5994.2012.02846.x.

PMID:
22647141
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk